CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1

Junjie Xu1,2,3, Lin Ji1,2,3, Yuelong Liang1,2,3, Zhe Wan1,2,3, Wei Zheng1, Xiaomin Song1, Kirill Gorshkov4, Qiming Sun5, Hui Lin1,2,3, Xueyong Zheng1,2,3, Jiang Chen1,2,3, Ren-an Jin1,2,3, Xiao Liang1,2,3 and Xiujun Cai1,2,3

Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the mechanisms underlying resistance have not been fully clarified. Here we report that a circular RNA, circRNA-SORE (a circular RNA upregulated in sorafenib-resistant HCC cells), plays a significant role in sorafenib resistance in HCC. We found that circRNA-SORE is upregulated in sorafenib-resistant HCC cells and depletion of circRNA-SORE substantially increases the cell-killing ability of sorafenib. Further studies revealed that circRNA-SORE binds the master oncogenic protein YBX1 in the cytoplasm, which prevents YBX1 nuclear interaction with the E3 ubiquitin ligase PRP19 and thus blocks PRP19-mediated YBX1 degradation. Moreover, our in vitro and in vivo results suggest that circRNA-SORE is transported by exosomes to spread sorafenib resistance among HCC cells. Using different HCC mouse models, we demonstrated that silencing circRNA-SORE by injection of siRNA could substantially overcome sorafenib resistance. Our study provides a proof-of-concept demonstration for a potential strategy to overcome sorafenib resistance in HCC patients by targeting circRNA-SORE or YBX1.

INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common primary liver tumor with an increasing global incidence. In 2018, HCC was the sixth most frequently diagnosed cancer and the fourth leading cause of cancer-related death worldwide. Sorafenib is the first FDA-approved targeted therapy for advanced HCC. A previous study showed that sorafenib prolonged the median overall survival (OS) by 2.3–3 months in advanced HCC patients that did not qualify for liver transplantation or resection. However, many HCC patients respond poorly to sorafenib or develop resistance after months of treatment. Sorafenib resistance in HCC is usually observed within 6 months of treatment. Compelling evidence has suggested that the primary and acquired resistance of sorafenib in HCC involves multiple mechanisms, including autophagy, epithelial–mesenchymal transition, cancer stem cells, tumor microenvironment, and epigenetic regulation, and a number of signaling pathways are suggested to be involved, such as Wnt/β-catenin, TGFβ, Ras/MEK/ERK, PI3K/Akt, TNFα/NF-κB, and JAK/STAT pathways. However, the mechanisms of sorafenib resistance, particularly in vivo and in HCC patients, have not been well studied and remain poorly understood.

Circular RNAs (circRNAs) are a class of endogenous noncoding RNAs (ncRNAs) that show complex tissue- and stage-specific expression within the eukaryotic transcriptome. Compared with linear ncRNAs, circRNAs are much more stable because of their closed-loop structure. Increasing evidence has indicated roles of circRNAs in various cancer-related processes, such as tumor formation, progression, relapse, and drug resistance. One of the best-known functions of circRNA is serving as miRNA sponges by directly binding miRNAs. For example, ciRS-7, the first extensively characterized circRNA, binds miR-7 and acts as a specific miR-7 inhibitor to regulate genes downstream of miR-7 in various cancers. Recent studies have demonstrated that circRNAs can also function by interacting with proteins. For example, circRNA-FOXO3 was shown to inhibit cell cycle progression by forming ternary complexes with p21 and CDK2.

Exosomes are a class of extracellular vesicles that play vital roles in numerous physiological and pathological processes, such as the maintenance of normal physiology, regulation of immune responses, and stimulation of tumor progression. Tumor-derived exosomes have important and fundamental roles in tumor progression. Recent studies have shown that tumor-derived exosomes may function as transmitters of drug resistance in different malignancies, including HCC. Moreover, circRNAs are enriched in exosomes in some cancers and could thus be used as a class of exosome-based cancer biomarkers. However, whether and how exosome-transmitted circRNAs are involved in cancer, especially in HCC, remain largely unknown.

In this work, we found that circRNA_104797, which we renamed as circRNA-SORE (a circular RNA upregulated in sorafenib-resistant...
HCC cells), is critical for maintenance and spread of sorafenib resistance in HCC. We found that circRNA-SORE is upregulated in sorafenib-resistant HCC cells and silencing circRNA-SORE substantially increases sorafenib-induced apoptosis in HCC cells. Mechanistic studies revealed that circRNA-SORE interacts with YBX1 in the cytoplasm, thus preventing PRP19-mediated YBX1 ubiquitination and degradation in the nucleus. Moreover, we found that circRNA-SORE is transmitted by exosomes, and silencing circRNA-SORE in different mouse models leads to a significant increase of sorafenib efficacy.

RESULTS

CircRNA-SORE is overexpressed in sorafenib-resistant HCC cells. Increasing evidence has indicated the involvement of circRNAs in various cancer-related processes. To examine possible circRNAs involved in mediating sorafenib resistance in HCC, we first established three sorafenib-resistant HCC cell lines (HepG2-SR, LM3-SR, and SKhep1-SR) by culturing cells with escalating doses of sorafenib (1–7 μM for HepG2-SR cells and 1–6 μM for LM3-SR and SKhep1 cells) for 12 months. We then confirmed sorafenib resistance in these three cell lines using the Real-time Cell Analysis xCELLigence System. Our results showed that the three sorafenib-resistant cell lines were insensitive to sorafenib and exhibited a faster growth rate under sorafenib treatment compared with their parental cell lines (Fig. 1a). Next, we conducted an Arraystar Human CircRNA Array analysis on parental and HepG2-SR cells as they showed most distinguished difference between parental and resistant cells, and identified 14 significantly upregulated and 14 downregulated circRNAs (circRNAs with fold change > 2 and p-values < 0.05) in HepG2-SR cells compared with parental control cells (Fig. 1b, c). Among the 14 upregulated circRNAs, circRNA_104797 had the most impact on sorafenib resistance in HCC cells. qPCR analysis confirmed that circRNA_104797 was consistently increased in all three sorafenib-resistant cell lines (Fig. 1d). Thus, we renamed circRNA_104797 as circRNA-SORE (a circular RNA upregulated in sorafenib-resistant HCC cells).

To identify the origin of circRNA-SORE, we checked the UCSC Genome Browser and found that circRNA-SORE (also named circRNA_104797 or circ_00087293) is generated from the backsplicing of the 7th and 8th exons of the TLE4 gene (Fig. 1e). To verify whether circRNA-SORE has a covalently closed continuous loop structure, we treated cells with actinomycin D (an RNA synthesis inhibitor) and found that circRNA-SORE was more stable than GAPDH (Fig. 1f). CircRNA-SORE was also resistant to RNase R, a linear RNA degrader, whereas the control linear GAPDH mRNA was not (Fig. 1g). Moreover, circRNA-SORE was mostly detected in non-mRNA samples (without a poly-A tail) rather than in mRNA samples (with a poly-A tail) (Fig. 1h), indicating that circRNA-SORE has no poly-A tail.

CircRNA-SORE is critical for maintaining sorafenib resistance. To investigate the possible role of circRNA-SORE in sorafenib resistance, we designed two siRNAs targeting the junction region of circRNA_104797. We found that circRNA-SORE siRNA-1 yielded a better silencing effect (Supplementary Fig. 1A, B), and thus we used siRNA-1 in our subsequent studies. The knockdown efficiency of circRNA-SORE siRNA-1 in all three sorafenib-resistant cell lines was confirmed (Supplementary Fig. 1C).

We next examined the effect of silencing circRNA-SORE on sorafenib resistance in HCC cells. As shown in Fig. 2a, depletion of circRNA-SORE by RNAi remarkably reversed sorafenib resistance in all three sorafenib-resistant HCC cell lines as reflected by cell viability assays. Colony formation assay produced similar results (Fig. 2b). These findings indicate an important role of circRNA-SORE in sorafenib resistance in HCC. To further confirm the function of circRNA-SORE in sorafenib resistance, real-time cell analyses were performed and area under the curve (ΔAUC) was calculated. We found that knocking down circRNA-SORE in HCC cells led to remarkable cell growth inhibitory effects in sorafenib-resistant HCC cells but had less of an impact on parental cell lines (Fig. 2c, d), further confirming a specific role of circRNA-SORE in the maintenance of sorafenib resistance.

Of note, after sorafenib treatment, the cell morphology of all three sorafenib-resistant cell lines transfected with si-circRNA-SORE exhibited signs of apoptosis, but these effects were not observed in the absence of sorafenib treatment or in parental cells (Fig. 2e and Supplementary Fig. S1D). Western blot assays revealed increased poly ADP-ribose polymerase (PARP) cleavage in all three sorafenib-resistant cell lines transfected with si-circRNA-SORE (Fig. 2f), indicating that silencing circRNA-SORE increases sorafenib-induced apoptosis in HCC cells. Propidium iodide/Annexin V apoptosis assays and TUNEL assays further confirmed the marked increase of apoptotic cells in the si-circRNA-SORE-transfected sorafenib-resistant cell lines (Fig. 2g, h and Supplementary Fig. 1E). Conversely, overexpressing circRNA-SORE in all three parental HCC cell lines using pLCDH-circRNA increased cell viability in response to sorafenib treatment (Supplementary Fig. 1F, G). Colony formation assays and propidium iodide/Annexin V apoptosis assays similarly showed that HCC parental cells acquired sorafenib resistance after circRNA-SORE overexpression (Supplementary Fig. 1H, I). Together these results demonstrate that circRNA-SORE plays a critical role in HCC resistance to sorafenib, and silencing circRNA-SORE substantially increases sorafenib-induced tumor cell apoptosis.

Considering the significance of circRNA-SORE in sorafenib resistance in HCC, we then considered whether circRNA-SORE could be a potential predictive marker for sorafenib efficacy in HCC patients. To investigate this possibility, we analyzed a group of 60 sorafenib-treated HCC patients who received liver resection and were treated with sorafenib after surgery from 2009 to 2013 (Table 1). We found that patients with lower circRNA-SORE expression were associated with better recurrence-free survival (RFS) (Fig. 2i and Table 2). This result suggests the potential of circRNA-SORE as a biomarker to predict the efficacy of sorafenib in HCC patients.

CircRNA-SORE functions by binding to YBX1 protein. One of the best-known functions of circRNA is to interrupt the mRNA splicing of its host gene. As exon-derived circRNAs and their host mRNAs are derived from the same pre-mRNA, circRNA can interrupt the splicing of its host mRNA, and the canonical pre-mRNA splicing can compete with the process of exon circularization. CircRNA-SORE is derived from the 7th and 8th exons of the TLE4 gene and generated into a circular form by back-splicing. To test whether circRNA-SORE functions through affecting the mRNA splicing of TLE4, we compared TLE4 mRNA levels between sorafenib-resistant and parental cells, but no significant difference was observed (Supplementary Fig. 2A). Next, we examined the effect of silencing circRNA-SORE on the expression of TLE4. As shown in Supplementary Fig. 2B, C, depletion of circRNA-SORE by siRNA had no apparent effect on either TLE4 mRNA or protein levels. These results indicate that circRNA-SORE may not function through regulating its host gene TLE4 expression to mediate sorafenib resistance in HCC.

Recent studies have shown that circRNA–protein interactions may play critical roles in a variety of diseases. Prediction of circRNA-SORE-binding proteins by the online database Circinteractome (https://circinteractome.irp.nia.nih.gov/) suggested that elf4A3, FMRP, IMP1, and IMP3 may bind circRNA-SORE. We then carried out RNA pull-down assays, which showed that circRNA-SORE indeed bound FMRP, IMP1, and IMP3, but not to elf4A3 (Supplementary Fig. 2D). To address the potential role of FMRP, IMP1, and IMP3 in sorafenib resistance in HCC, we silenced these genes using siRNA knockdown (Supplementary Fig. 2E, F).
Fig. 1  CircRNA-SORE is overexpressed in sorafenib-resistant HCC cells.  
a Three sorafenib-resistant HCC cell lines (HepG2-SR, LM3-SR, and SKhep1-SR) were established and confirmed by the Real-time Cell Analysis xCELLigence System (Roche Applied Sciences). Curves demonstrate the inhibitory effect of sorafenib on parental (P) and sorafenib-resistant (SR) cell lines. 
b Hierarchical clustering of 14 upregulated circRNAs and 14 downregulated circRNAs in HepG2-SR cells compared with parental HepG2 cells by Arraystar Human CircRNA Array analysis. CircRNAs with fold change >2 and p < 0.05 were selected as significantly different. 
c Scatter plots (left panel) and volcano plots (right panel) of the differentially expressed circRNAs. Red dots indicate differentially expressed circRNAs (p < 0.05 and fold change > 2). 
d CircRNA_104797 levels (normalized by GAPDH) in parental (P) and resistant (R) cell lines treated with the indicated concentrations of sorafenib (7 μM for HepG2, 6 μM for LM3 and SKhep1) for 72 h. 
e Diagram illustrating back-splicing of circRNA-SORE from the TLE4 host gene. 
f Time-course of the relative expression of circRNA-SORE and TLE4 in HepG2-SR cells treated with actinomycin D (10 μg/mL). 
g qPCR analysis of circRNA-SORE and GAPDH mRNA in HepG2-SR, LM3-SR and SKhep1-SR cells with or without RNase R treatment for 30 min at 37 °C. 
h Relative expression of circRNA-SORE in mRNA and non-mRNA samples in the indicated cell lines. Three independent experiments with three technical repetitions were performed. Data are expressed as mean ± SEM (error bars). Statistical analyses used Student’s t test. ***p < 0.001. NS not significant.
However, silencing of FMRP, IMP1, and IMP3 had no effect on sorafenib resistance (Supplementary Fig. 2G), indicating that these proteins are not involved in the function of circRNA-SORE in sorafenib resistance in HCC.

To further investigate potential interacting protein(s) of circRNA-SORE involved in sorafenib resistance, we next carried out LC-MS/MS analysis on circRNA-SORE pull-down samples from HepG2-SR cells and compared it with the controls. The results identified 179 circRNA-SORE-binding proteins (Fig. 3a). To identify proteins regulated by circRNA-SORE, we performed LC-MS/MS analysis on lysates from circRNA-SORE-silenced HepG2-SR cells and compared it with the control cells, which identified 129 upregulated and 301 downregulated proteins (fold change > 2 and p < 0.05) (Fig. 3b). Gene Ontology Analysis of the dysregulated proteins in circRNA-SORE-silenced HepG2-SR cells indicated that these proteins are associated with a variety of functions, such as response to drug, cell adhesion and cell migration (Supplementary Fig. 2H). Venn analysis of the circRNA-SORE pull-down proteins and the dysregulated proteins in the circRNA-SORE-silenced group led to the identification of ten overlapping proteins that analysis on lysates from circRNA-SORE-silenced HepG2-SR cells and compared it with the control cells, which identified 129 upregulated and 301 downregulated proteins (fold change > 2 and p < 0.05) (Fig. 3b). Gene Ontology Analysis of the dysregulated proteins in circRNA-SORE-silenced HepG2-SR cells indicated that these proteins are associated with a variety of functions, such as response to drug, cell adhesion and cell migration (Supplementary Fig. 2H). Venn analysis of the circRNA-SORE pull-down proteins and the dysregulated proteins in the circRNA-SORE-silenced group led to the identification of ten overlapping proteins that...
Fig. 2  CircRNA-SORE is critical for maintaining sorafenib resistance. a Relative cell viability of three HCC sorafenib-resistant cell lines with circRNA-SORE siRNA knockdown (si-circRNA-SORE) compared with controls treated with the indicated concentrations of sorafenib (7 μM for HepG2-SR, 6 μM for LM3-SR and SKhep1-SR) for 72 h. b Colony formation assays in three HCC sorafenib-resistant cell lines with or without sh-circRNA-SORE. Cells were all treated with sorafenib (7 μM for HepG2-SR, 6 μM for LM3-SR and SKhep1-SR) for 24 h in complete media, washed with PBS and cultured in complete media for another 7 days. c HepG2-P and HepG2-SR cell lines transfected with si-circRNA-SORE or negative control siRNA (si-NC) were treated with sorafenib. Cell viability was recorded by Real-time Cell Analysis xCELLigence System and three technical repetitions were performed. ΔAUC (difference of area under curve) = (AUC NC) – (AUC si-circRNA-SORE). Each technical repetition yields a ΔAUC, and t tests were performed. d Similar to (c) except no sorafenib was added. e Brightfield images (objective magnification = 10) showing cell morphology of three sorafenib-resistant cell lines with or without si-circRNA-SORE or sorafenib at the indicated concentrations (7 μM for HepG2-SR, 6 μM for LM3-SR and SKhep1-SR) for 72 h. Scale bar, 20 μm. f Western blot analysis of sorafenib-resistant cell lines transfected with si-circRNA-SORE using PARP antibody (upper) and β-tubulin antibody (lower). g PI/Annexin V flow cytometry analysis (10,000 cells) of sorafenib-resistant cells transfected with si-NC or si-circRNA-SORE. h TUNEL staining (green) of three sorafenib-resistant cell lines transfected with si-NC or si-circRNA-SORE. Nuclei were stained with DAPI (blue). Scale bar, 20 μm. i Kaplan–Meier recurrence-free survival analysis for sorafenib-treated HCC patients with low and high circRNA-SORE expression. The median circRNA-SORE expression was used as cut-off for high- and low-expression groups. Three independent experiments with three technical repetitions were performed. Data are expressed as mean ± SEM (error bars). Statistical analyses used Student’s t test and Kaplan–Meier survival analysis. *p < 0.05, and **p < 0.01

Table 1. CircRNA-SORE expression and clinicopathological factors in HCC patients

| Factors          | Low circRNA-SORE expression (95% CI) (n = 30) (N %) | High circRNA-SORE expression (95% CI) (n = 30) (N %) | p value |
|------------------|-----------------------------------------------------|-----------------------------------------------------|---------|
| Age (mean)       | 46.77 (42.32–51.21)                                 | 48.10 (43.83–52.67)                                 | 0.459   |
| Gender           |                                                     |                                                     |         |
| Male             | 29 (96.7)                                           | 27 (90.0)                                           |         |
| Female           | 1 (3.3)                                             | 3 (10.0)                                            | 0.605   |
| HBV              |                                                     |                                                     |         |
| +                | 9 (30.0)                                            | 12 (40.0)                                           |         |
| −                | 21 (70.0)                                           | 18 (60.0)                                           | 0.417   |
| Fibrosis         |                                                     |                                                     |         |
| +                | 21 (70.0)                                           | 21 (70.0)                                           |         |
| −                | 9 (30.0)                                            | 9 (30.0)                                            | 1.000   |
| Tumor size       |                                                     |                                                     |         |
| (Large) ≥50 mm   | 28 (93.3)                                           | 30 (100.0)                                          | 1.000   |
| (Small) <50 mm   | 2 (6.7)                                             | 0 (0.0)                                             |         |
| Tumor number     |                                                     |                                                     |         |
| >1               | 5 (16.7)                                            | 2 (6.7)                                             |         |
| 1                | 25 (83.3)                                           | 28 (93.3)                                           | 0.041   |
| Lymph node metastasis | 1 (3.3)                        | 0 (0.0)                                             |         |
| Absent           | 29 (96.7)                                           | 30 (100.0)                                          | 1.000   |
| Vascular invasion|                                                     |                                                     |         |
| Present          | 14 (46.7)                                           | 11 (36.7)                                           |         |
| Absent           | 16 (53.3)                                           | 19 (63.3)                                           | 0.432   |
| Macro-vascular invasion | 5 (16.7)                        | 4 (13.3)                                             |         |
| Absent           | 25 (83.3)                                           | 26 (86.7)                                           | 0.000   |
| Micro-vascular invasion | 12 (40.0)                        | 11 (36.7)                                             |         |
| Absent           | 18 (60.0)                                           | 19 (63.3)                                           | 0.791   |
| Extrahepatic metastasis | 0 (0.0)                        | 1 (3.3)                                             |         |
| Absent           | 30 (100.0)                                          | 29 (96.7)                                           | 0.000   |
| Satellite foci   |                                                     |                                                     |         |
| Present          | 3 (10.0)                                            | 2 (6.7)                                             |         |
| Absent           | 27 (90.0)                                           | 28 (93.3)                                           | 0.999   |
| Stage            |                                                     |                                                     |         |
| Early            | 22 (73.3)                                           | 23 (76.7)                                           | 0.766   |
| Late             | 18 (62.7)                                           | 7 (23.3)                                            | 0.766   |
| YBX1a            |                                                     |                                                     |         |
| /−               | 27 (90.0)                                           | 18 (60.0)                                           |         |
| +/+ /−/−/++      | 3 (10.0)                                            | 12 (40.0)                                           | 0.007   |

The median circRNA-SORE expression was used as cut-off for high- and low-expression groups.

aBureau of Medical Administration, National Health and Family Planning Commission of the People’s Republic of China.

bYBX1 levels were defined by immunohistochemical staining theoretically should not only bind to but also be regulated by circRNA-SORE (Supplementary Table 2). YBX1, one of the ten candidates, is a nucleic acid-binding protein and more importantly, circRNA-SORE harbors the specific binding sequence (CCAAAT) for YBX1. Moreover, KEGG pathway analysis of circRNA-SORE-dysregulated proteins showed a significant enrichment in YBX1-related signaling (p < 0.05, Fig. 3c). These results strongly indicated that YBX1 is a binding protein for circRNA-SORE. We then performed RNA pull-down and immunoprecipitation assays and confirmed the specific binding of circRNA-SORE to YBX1 (Fig. 3d, e and Supplementary Fig. 2i, j). To better clarify the interactions between circRNA-SORE and YBX1, morpholino antisense oligos (MAO) targeting the Y-box sequence (CCAAAT) in circRNA-SORE were transfected into HepG2-SR cells. As shown in Fig. 3f, g, RNA pull-down and immunoprecipitation assays showed that targeting the Y-box sequence in circRNA-SORE blocked its binding to YBX1, suggesting circRNA-SORE binds YBX1 via the Y-box sequence. Moreover, circRNA-SORE-M, in which the YBX1-binding sequence was mutated, showed reduced binding capacity with YBX1 in RNA pull-down and RIP assays (Fig. 3h, i). CircRNA-SORE FISH and YBX1 immunofluorescence experiments also revealed the colocalization of circRNA-SORE and YBX1 in HepG2-SR cells, which mainly occurred in the cytoplasm (Fig. 3j). These results confirmed an interaction of circRNA-SORE with YBX1.

YBX1 has a well-established role in oncogenesis.20 Analysis of RNA sequencing data from The Cancer Genome Atlas (TCGA) project11 revealed an increase of YBX1 levels in HCC tumors compared with normal liver tissues (Supplementary Fig. 2k, l). Moreover, survival analysis showed that patients with higher YBX1 levels had worse OS compared with those with lower YBX1 levels (Fig. 3k). Comparison of YBX1 levels between sorafenib-resistant and parental HepG2 cells revealed elevated YBX1 levels in HepG2-SR cells (Fig. 3l), suggesting a role for YBX1 in sorafenib resistance. To further examine the role of YBX1, we silenced YBX1 using two sets of siRNAs, which both remarkably decreased protein levels of YBX1 and its downstream target genes including AKT, Raf1, ERK, c-Myc, and TGF-β1 (Fig. 3m). si-YBX1-1, which showed better knockdown efficiency, was used for subsequent experiments. We next examined the effect of silencing YBX1 on HCC resistance to sorafenib. We found that knocking down YBX1 resulted in attenuated sorafenib resistance, increased apoptosis, and disrupted cell morphology in all three sorafenib-resistant HCC cell lines (Fig. 3o and Supplementary Fig. 2m). Notably, silencing circRNA-SORE markedly decreased the protein levels of YBX1 and its downstream target genes AKT, Raf1, ERK, c-Myc, and TGF-β1 in the three sorafenib-resistant cell lines (Fig. 3p), and the effect of silencing circRNA-SORE on HCC sensitivity to sorafenib could be, to a large extent, rescued by overexpressing YBX1 (Fig. 3q). Importantly, the effect of overexpressing circRNA-SORE on sorafenib resistance was attenuated upon silencing YBX1 in HCC.
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by...

Table 2. Results of univariate and multivariate analysis of clinicopathological factors for recurrence-free survival (Cox proportional hazard model)

| Variables Univariate analysis | Multivariate analysis (circRNA-SORE) | Multivariate analysis (YBX1) |
|-----------------------------|--------------------------------------|-----------------------------|
|                             | HR 95% CI    | p value | HR 95% CI    | p value | HR 95% CI    | p value |
| Age (Old/Young)             | 0.987 0.958–1.015 | 0.356 | 2.830 0.756–10.591 | 0.122 | 2.034 0.860–4.811 | 0.106 |
| Gender (Female/Male)        | 1.641 0.496–5.431 | 0.417 | 2.648 1.059–6.618 | **0.037** | 1.938 0.814–4.612 | 0.135 |
| HBV (+/−)                   | 1.661 0.795–3.472 | 0.177 | 1.415 0.626–3.202 | 0.404 | 1.597 0.785–3.250 | 0.196 |
| Fibrosis (+/−)              | 2.035 0.869–4.764 | 0.101 | 2.053 0.997–4.227 | **0.051** | 2.281 1.074–4.845 | **0.032** |
| Stage* (Late/ Early)        | 1.998 0.958–4.169 | 0.065 | 2.563 1.214–5.414 | **0.014** | 2.972 1.380–6.402 | **0.005** |

As a positive correlation of YBX1 protein level and circRNA-SORE expression level was observed in Table 1, to avoid interactions between factors, the multivariate analyses were performed respectively for circRNA-SORE and YBX1 levels defined by immunohistochemical staining.

To identify the potential E3 ubiquitin ligase involved in circRNA-SORE-mediated YBX1 stabilization, we performed mass spectrometric analysis of YBX1 immunoprecipitated complexes from HepG2-SR cells transfected with si-circRNA-SORE compared with controls (Fig. 4f). We cross-referenced the results with the E3 ubiquitin ligase databases (UbiNet, ESBL, and E3NET) and found that two E3 ligases, Pre-MRNA Processing Factor 19 (PRP19) and Notchless protein homolog 1 (NLE1), were identified exclusively in the si-circRNA-SORE-transfected cells by grading mass spectrum, but only PRP19 was also identified by non-grading mass spectrum in the si-circRNA-SORE-transfected cells (Fig. 4g). In addition, other components of the PRP19 complex (also known as the NTC, nineteen complex), including CDC5L, PLRG1, and SPF27, were also found exclusively in YBX1- immunoprecipitated complexes from lysates of si-circRNA-SORE-transfected cells (Fig. 4h).

PRP19 complex, a ubiquitin ligase, mediates protein degradation through the ubiquitin proteasome pathway.25 To confirm whether PRP19 is the E3 ligase for YBX1, we first tested the effect of silencing PRP19 on YBX1 protein level. We found that YBX1 protein level was increased in HepG2-SR cells transfected with siRNA targeting PRP19 in a concentration- and time-dependent manner (Fig. 4i). These results indicate that PRP19 mediates YBX1 degradation. Consistent with this result, CHX chase assays showed that silencing PRP19 could stabilize YBX1 protein levels (Fig. 4j). Moreover, the ubiquitination of YBX1 was remarkably decreased in HepG2-SR cells upon PRP19 silencing (Fig. 4k). In particular, silencing PRP19 rescued the decrease of YBX1 mediated by si-circRNA-SORE (Fig. 4l). Together, these results suggest that PRP19-mediated YBX1 ubiquitination and degradation is involved in the circRNA-SORE-YBX1 regulation.

Next, we examined the localization of circRNA-SORE, PRP19 and YBX1. As shown in Fig. 4m, circRNA-SORE, similar to GAPDH mRNA, was primarily detected in the cytoplasm of HCC cells rather than in the nucleus. Fluorescence in situ hybridization (FISH) for circRNA-SORE further confirmed its cytoplasmic localization in the three HCC cell lines (Fig. 4n). More importantly, we found that YBX1 was partially translocated from the cytoplasm to the nucleus upon transfection with si-circRNA-SORE (Fig. 4o). Consistent with this finding, immunofluorescence experiments also showed enhanced nuclear localization of YBX1 in cells transfected with si-circRNA-SORE compared with the controls (Fig. 4p). Notably, a previous study reported that PRP19 is located in the nucleus.26 These results suggest that circRNA-SORE may prevent YBX1 from translocating into the nucleus, where it is ubiquitinated and degraded by PRP19.
To further confirm the inhibitory effect of circRNA-SORE on the YBX1-PRP19 interaction, MAOs targeting the Y-box motif were transfected in HepG2-SR cells. As shown in Fig. 4q, MAOs partially rescued the nuclear translocation of YBX1 upon treatment of si-circRNA-SORE. Additionally, overexpression of wild-type circRNA-SORE decreased the interaction between PRP19 and YBX1, whereas overexpression of the mutant circRNA-SORE had no effect (Fig. 4r). Based on these results, we proposed a model in which circRNA-SORE binds to YBX1 in the cytoplasm, thus preventing YBX1 from translocating to the nucleus to interact with and subsequently be degraded by PRP19 (Fig. 4s).
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by...

CircRNA-SORE transmits sorafenib resistance by exosomes. Recent studies have demonstrated that circRNAs are enriched in exosomes. Other reports showed that drug resistance can be transmitted by exosomes. We next evaluated exosomal circRNA-SORE expressions in the blood of nine HCC patients prior to sorafenib treatment. As shown in Fig. 5a, patients with relatively lower circRNA-SORE expression had a higher response rate to sorafenib (80%) compared with patients with higher circRNA-SORE expression (25%), indicating that exosomes might be involved in circRNA-SORE-mediated sorafenib resistance in HCC. To test this possibility, we isolated and identified exosomes from the culture media of HepG2-SR and HepG2-P cells (Fig. 5b-d). qRT-PCR revealed that exosomes isolated from HepG2-SR cell culture media contained more circRNA-SORE than those from HepG2-P cell culture media (Fig. 5e). Moreover, circRNA-SORE was substantially more enriched in exosomes from the culture media of sorafenib-resistant cells than in the cell cytosol (Fig. 5f), further supporting that exosomes are involved in transmitting circRNA-SORE. Furthermore, we found that parental HCC cells treated with exosomes from the sorafenib-resistant cell culture media showed higher levels of circRNA-SORE and were more resistant to sorafenib than cells treated with the exosomes from parental cell culture media (Fig. 5g, h). This effect was partially rescued by silencing circRNA-SORE in exosome-treated parental HCC cells (Fig. 5i). These results suggest a role for exosomes in spreading circRNA-SORE-mediated sorafenib resistance among HCC cells.

In vitro engineered exosomes carrying siRNAs targeting circRNA-SORE represent potential tumor-specific and molecularly targeted therapies in HCC patients. Novel exosome-based cancer therapeutic strategies have been extensively reported, including the preclinical use of dendritic cell-derived exosomes for HCC immunotherapy and stellate cell-derived miR-335-Sp-loaded exosomes for HCC treatment. Notably, we found that parental HCC cells treated with exosomes from circRNA-SORE-silenced cells were more sensitive to sorafenib than cells treated with exosomes from control cells (Fig. 5j, k). The targeting nature of exosomes also makes them ideal transmitters for delivering therapeutic agents, such as therapeutic siRNAs.

To further investigate the involvement of exosomes in the function of circRNA-SORE in vivo, we subcutaneously implanted SKhep1-P cells in BALB/c nude mice and then treated mice with sorafenib for 4 weeks (Fig. 5l). Exosomes from the culture media of SKhep1-P and SKhep1-SR cells were then locally injected around the tumor implantation site. After 4 weeks, mice were sacrificed, and tumors were harvested. The tumors from mice receiving exosomes from SKhep1-SR cells were significantly larger than those from mice receiving exosomes from SKhep1-P cells (p < 0.05), indicating an enhanced drug resistance in the SKhep1-SR exosome-treated group. Together these results demonstrate that exosomes are crucial for spreading circRNA-SORE-mediated sorafenib resistance among HCC tumor cells.

Silencing circRNA-SORE substantially improves sorafenib efficacy in vivo

To further confirm the significance of circRNA-SORE in mediating HCC resistance to sorafenib in vivo, we used three different mouse models: an orthotopic sorafenib-resistant cell line-derived xenograft (CDX) model, a subcutaneous sorafenib-resistant CDX model and a sorafenib-resistant patient-derived xenograft (PDX) model. Mice with orthotopic implantation of SKhep1-SR cells expressing shcircRNA-SORE were markedly more sensitive to sorafenib treatment than mice implanted with SKhep1-SR-shNC cells (Fig. 6a). In the second mouse model, we locally injected in vivo grade cholesterol-conjugated RIG-1 si-circRNA-SORE around the LM3-SR cell implantation site in BALB/c nude mice, which significantly increased the sensitivity of mice to sorafenib treatment compared with injection of control siRNA (p < 0.001, Fig. 6b). In the third model, the sorafenib-resistant PDX model, local injection of in vivo grade cholesterol-conjugated RIG-1 si-circRNA-SORE around the PDX implantation site resulted in significant increases in the sensitivity to sorafenib treatment compared with injection of control siRNA (p < 0.001, Fig. 6c). Moreover, similar to the in vitro results, YBX1 level was reduced by si-circRNA-SORE treatment, both in the LM3-SR xenograft and the PDX model (Fig. 6d, e). Overall, these results demonstrated the in vivo effect of depriving circRNA-SORE on enhanced sorafenib sensitivity in three animal HCC models, further supporting the clinical potential of silencing circRNA-SORE to improve sorafenib efficacy in HCC patients.
DISCUSSION
HCC is a highly therapy-resistant cancer and surgery is currently the primary treatment option but is only suitable for HCC patients who are diagnosed at an early stage. However, HCC patients are frequently diagnosed at advanced stages, and the interventions for these patients, including molecular-targeted therapies, are limited and show low efficacy.\(^{27,28}\) As the first FDA-approved molecular-targeted drug, sorafenib provided a 3-month prolongation of the median OS time according to The Sorafenib HCC Assessment Randomized Protocol (SHARP) trial\(^{29}\) and the Phase III Sorafenib Asia-Pacific (AP) trial.\(^{2}\) However, sorafenib resistance, which often develops within 6 months, has caused widespread...
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by...

Xu et al.

**Fig. 4** CircRNA-SORE stabilizes YBX1 by preventing its PRP19-mediated degradation. **a** qPCR analysis of YBX1 mRNA expression in HepG2-SR cells transfected with si-NC or si-circRNA-SORE. **b** Western blot analysis of YBX1 and β-tubulin in HepG2-SR cells transfected with si-NC or si-circRNA-SORE and treated with cycloheximide (CHX) (200 μM). **c** Western blot analysis of YBX1 and β-tubulin in HepG2-SR cells transfected with or without si-circRNA-SORE following proteasome inhibition with MG132 treatment (20 μM) for 3 h. **e** YBX1 was immunoprecipitated (IP) from HepG2-SR cells transfected with or without si-circRNA-SORE and with or without MAO treatment and treated with MG132 (20 μM) for 3 h. Immunoblotting (IB) was performed for ubiquitin (top) and YBX1 (bottom). **f** Schematic illustration of mass spectrometric analysis of YBX1. **g** Western blot analysis of YBX1 and β-tubulin in HepG2-SR cells transfected with si-PRP19 and si-NC and treated with cycloheximide (CHX) (200 μM). **k** YBX1 was immunoprecipitated (IP) from HepG2-SR cells transfected with the indicated siRNAs and treated with MG132 (20 μM) for 3 h. Immunoblot (IB) was performed with the indicated antibodies. **j** Western blot analysis of PRP19, YBX1 and β-tubulin in HepG2-SR cells transfected with or without si-circRNA-SORE or si-PRP19. **m** Relative expression of circRNA-SORE and GAPDH mRNA in the cytoplasmic (C) and nuclear (N) fractions in the indicated cell lines. **n** Localization of circRNA-SORE (green) was examined in HCC cell lines using FISH. Nuclei are shown in blue. Scale bar, 20 μm. **o** Western blot analysis of YBX1, GAPDH and H2B in cytoplasmic (C) and nuclear (N) fractions in HepG2-SR cells transfected with or without si-circRNA-SORE. **p** Top: the average YBX1 nuclear fractions in HepG2-SR transfected cells with si-circRNA-SORE or si-NC from five different confocal microscopic fields of view. Bottom: merged images of YBX1 immunofluorescence (green) and nuclei staining (DAPI, blue) in HepG2-SR cells transfected with si-circRNA-SORE or si-NC. Yellow (merged signal) indicates the nuclear fraction of YBX1 in HepG2-SR cells. Scale bar, 20 μm. **q** Western blot analysis of YBX1, β-tubulin and H3 in the cytoplasmic (C) and nuclear (N) fractions in HepG2-SR cells transfected with or without si-circRNA-SORE and with or without MAO treatment. **r** Western blot analysis of PRP19 immunoprecipitated by YBX1 in HepG2-P cells transfused with pLcDH-circRNA-SORE (NC), pLcDH-circRNA-SORE (OE-circRNA-SORE), or pLcDH-circRNA-SORE-M (OE-circRNA-SORE-M, with mutant YBX1-binding sites). **s** Schematic of the proposed model. CircRNA-SORE binds to YBX1 in the cytoplasm, thus preventing YBX1 from translocating to the nucleus to interact with and subsequently be degraded by PRP19. Three independent experiments with three technical repetitions were performed. Data are expressed as mean ± SEM (error bars). Statistical analyses used Student’s t test. *p < 0.05, ***p < 0.001 and ****p < 0.0001

CircRNAs, which were identified more than 20 years ago, were initially thought to have low abundance and result from alternative splicing errors during transcription. Based on high-throughput sequencing and novel computational approaches, circRNAs derived from exons or introns are now recognized as widespread and diverse endogenous eukaryotic ncRNAs that participate in various cancer-related processes. CircRNAs have a covalently closed-loop structure with neither 5’ to 3’ polarity nor a polyadenylated tail, which makes circRNAs more stable than the linear counterparts. Moreover, circRNAs contain multiple binding sites to trap specific molecules and thus show more specific and efficient functionality compared with miRNAs. In particular, the tissue- and stage-specific expression of circRNAs makes these molecules suitable therapeutic target candidates. In our study, local injection of in vivo-grade cholesterol-conjugated RIG-I si-circRNA-SORE significantly increased the sensitivity of sorafenib treatment in HCC mouse models, indicating the promising clinical application of siRNA-mediated regulation of circRNA-SORE in HCC patients. Indeed, the U.S. Food and Drug Administration recently approved the first RNAi therapeutic, Onpattro infusion, for the treatment of polyneuropathy, a peripheral nerve disease. Our findings suggest the promising prospect of in vivo delivery of siRNA targeting circRNA-SORE by transarterial chemobolization or other means to enhance sorafenib efficacy in HCC patients.

Previous studies reported that exon-derived circRNAs are located predominantly in the cytoplasm. Consistent with this study, we also found that circRNA-SORE is predominantly located in the cytoplasm of HCC cells. Moreover, we identified YBX1 as the binding partner for circRNA-SORE in the cytoplasm. YBX1, also known as YB-1, is highly correlated with tumor cell proliferation, drug resistance, cancer progression, and prognosis in various types of cancer. Our results showed that circRNA-SORE binds to YBX1 in the cytoplasm, thus preventing YBX1 nuclear translocation and consequently blocking its PRP19-mediated ubiquitination and degradation. PRP19 contains a U-box domain that is structurally related to the RING finger motif found in certain E3 ubiquitin ligases and exhibits E3 ligase activity. PRP19 functions in protein degradation and may transport its substrates to the proteasome by binding to proteasomal subunits. Although other components of the PRP19 complex were also found exclusively in YBX1-immunoprecipitated complexes from lysates from si-circRNA-SORE-transfected cells, whether PRP19 functions alone or as a part of a complex in mediating protein ubiquitination is unclear. Further studies are required to clarify whether other components of the PRP19 complex are also involved in YBX1 degradation.

Recent studies demonstrated that tumor-derived exosomes could function as transmitters of drug resistance in different malignancies. Moreover, a recent study showed that exosome-derived circRNAs were stably enriched in exosomes, and adipose exosomes carrying circRNAs were found to promote the growth of HCC by targeting USP7. In line with these findings, we have found that circRNA-SORE is enriched and transmitted by exosomes, enabling the spread of sorafenib resistance among HCC cells. The stable properties of exosomes and circRNAs may make exosome-carrying-circRNA-SORE a promising biomarker in liquid biopsy for the early detection and noninvasive surveillance of HCC.

In conclusion, our results demonstrate that circRNA-SORE plays a critical role in the maintenance and transmission of sorafenib resistance in HCC (Fig. 6). CircRNA-SORE functions by preventing PRP19-mediated YBX1 degradation, thereby affecting the expression of downstream gene targets of YBX1 including AKT, Raf1, ERK, c-Myc, and TGF-β1. CircRNA-SORE is transported by exosomes, which enables transmission of sorafenib resistance among HCC cells. Local siRNA-mediated silencing of circRNA-SORE effectively overcomes sorafenib resistance and increases therapeutic efficacy in different HCC mouse models. Together, these findings suggest concerns and significantly limits the clinical benefit of sorafenib in HCC patients. Despite great efforts in the development of combined therapies to improve sorafenib efficacy, the overall outcomes of liver cancer treatment are still far from satisfactory. Therefore, there is an urgent need to further explore the mechanisms underlying sorafenib resistance for the development of more effective combination therapies. In this study, we uncovered a previously unrecognized role of a circRNA, circRNA-SORE, in maintaining and transmitting sorafenib resistance in HCC. These results provide a new potential combination therapy strategy to overcome sorafenib resistance in HCC.
Fig. 5 CircRNA-SORE transmits sorafenib resistance by exosomes. a Exosomes were extracted from the blood of nine HCC patients prior to sorafenib treatment, and exosomal circRNA-SORE expressions were evaluated by qPCR assays. Lower and higher circRNA-SORE expressions were stratified by the average expression among the nine patients. Response to sorafenib was defined as a complete response, partial response or stable disease for >3 months. b Negative staining electron micrograph of exosomes isolated from HepG2-SR culture media. Scale bar, 200 nm. c Size distribution of exosomes by NanoSight NS300 instrument. d Western blot analysis for positive exosome markers (HSP70, TSG101, CD9 and CD63) and negative exosome marker (Calnexin). e qPCR analysis of exosomal circRNA-SORE isolated from sorafenib-resistant and parental cell culture media. f qPCR analysis of circRNA-SORE isolated from sorafenib-resistant cell culture media (M) and cells (C). g Schematic showing that exosomes were isolated from parental and sorafenib-resistant cells (P-exo and SR-exo, respectively) and used to treat (30 μg) parental cells for 24 h. The exosome-treated parental cells were then transfected with si-NC or si-circRNA-SORE and treated with sorafenib for 48 h. h, i Exosomes were isolated from parental and sorafenib-resistant cells (P-exo and SR-exo, respectively) and used to treat parental cells for 24 h. The exosome-treated parental cells were then transfected with si-NC or si-circRNA-SORE and treated with sorafenib for 48 h. Charts show qPCR results of circRNA-SORE expression and cell viability in exosome-treated parental cells. j Schematic showing that HepG2-SR cells were treated with si-NC or si-circRNA-SORE before the culture media were harvested for exosome isolation and subsequent exosome treatments on parental cells. The chart shows the cell viability in exosome-treated parental cells. k BALB/c nude mice (4- to 6-week-old males) were subcutaneously injected with SKhep1-P cells. On week 4, the mice were treated with sorafenib (30 mg/kg/day) by oral gavage and exosomes (80 μg twice a week for 4 weeks) from SK-hep1-SR or SK-hep1-P cell culture media by injection at the implantation site twice a week for 4 weeks. Animals were sacrificed on week 8 and xenografts were isolated and measured. Three independent experiments with three technical repetitions were performed. Data are expressed as mean ± SEM (error bars). Statistical analyses used Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
a potential clinical application of circRNA-SORE siRNA in combination with sorafenib to treat patients with advanced HCC. More clinical samples, especially more blood samples from HCC patients before and after sorafenib treatment, are required to fully establish the clinical value of targeting circRNA-SORE or YBX1 for overcoming sorafenib resistance in HCC patients.

**MATERIALS AND METHODS**

RNA pull-down

For biotinylated RNA pull-down assays, transfected HepG2-SR cell lysates were incubated with MyOne™ Dynabead® Streptavidin C1 beads (Invitrogen, USA) at 4 °C for 1 h. For biotinylated-probe pull-down assays, MyOne™ Dynabead® Streptavidin C1 beads were
incubated with HepG2-SR cell lysate at 4°C for 1 h for preclearance. The 3’ biotin-labeled circRNA-SORE probe (5’-GAGTGTGTCGCTGTAGGAGTC-3’-biotin) was synthesized by Tsingke Biotech (Beijing, China) and incubated with the beads at room temperature for 10 min for immobilization. The biotinylated beads were incubated with HepG2-SR cell lysates at 4°C overnight. The beads were then magnetically separated and washed five times. For western blot detection, the beads were boiled in SDS buffer for protein/peptide isolation. For mass spectrum assays, the beads were incubated with non-ionic water in 70°C for 5 min.

Silencing and overexpression of circRNA-SORE

CircRNA-SORE siRNA targeting the junction region of the circRNA-SORE sequence was synthesized by Ribobio (Guangzhou, China). The short hairpin shcircRNA-SORE sequence (based on the same sequence as si-circRNA-SORE) was cloned into GV248.

The pLCDH-cir vector (Geneseed, Guangzhou, China) was used to construct the circRNA-SORE overexpression plasmid (OE-circRNA-SORE). The linear sequence of circRNA-SORE together with the flanking circRNA inducing sequence was amplified and subcloned into EcoRI and BamHI sites of pLCDH-cir, and the resulting vector was termed pLCDH-cir-SORE. pLCDH-circRNA-SORE-M has a mutated YBX1-binding site. The sequences of mutant constructs are listed in Supplementary Table 1. The primers were as follows:

Primer-F: CCGAATTCTCCAGATTATGCTTCTTCCAGCACGACAACACTCAGGCCCA and Primer-R: CGGATCTTCAGGAAAAATATTATTCCCTTGAGGAGTCTCGTCTC.

GV248-shcircRNA-104797, pLCDH-cir, pLCDH-cir-104797, pSX2 packaging plasmid, and pMD2G envelope plasmids were transfected into 293 T cells using the standard calcium phosphate transfection method for 48 h to produce lentivirus. Viruses were collected from supernatant and concentrated by density gradient centrifugation. Viruses were frozen at −80°C for later use.

Tissue samples

For mouse studies, we collected all samples from the NOD/SCID mice and BALB/c nude mice for hematoxylin-eosin staining and immunohistochemistry staining according to the designated antibody protocols. Tissue samples (60 cases) and blood samples (9 cases) were obtained from randomly selected sorafenib-treated HCC patients. All patients signed informed consent for the use of tissues for scientific research. We reviewed pathology records to identify samples with confirmed HCC. Low- and high-circRNA-SORE expression groups were classified using median expression as a cut-off value. The current study conformed to the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the Sir Run-Run Shaw Hospital.

Additional methods information can be found in Supplementary Materials.

DATA AVAILABILITY

Additional data collected during this study are available from the corresponding authors upon reasonable request.

ACKNOWLEDGEMENTS

We thank Xu Feng, Qijiang Mao, Di Wu, Yu Pan, Bin Zhang, Yangyang Xie, Jingwei Cai and Junzhao Zheng who collected the clinical samples and Lin Li, Junfang Ji, Yin Sun, Shunjie Xia, Shi Jiang, Zhongjie Lin, Dong Cen, Longbo Zheng and Junjie Hong for giving comments and suggestions to this study. We thank Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript. This research was supported by the National Natural Science Foundation of China under Grant No. 81772546 (to X.C.), No. 81872804 (to X.C.) and No. 81902367 (to J.X.), Zhejiang Provincial Natural Science Foundation of China under Grant No. LQ19H160026 (to J.X.) and LGF18H160011 (to Y.L.), China Postdoctoral Science Foundation under Grant No. 2020M671755 (to J.X.), Key Research and Development Project of Zhejiang Province under Grant No. 2018C03083 (to X.C.), Zhejiang Clinical Research Center of Minimally Invasive Diagnosis and Treatment of Abdominal Diseases under Grant No. 2018B350003 (to X.C.), Special fund for basic scientific research operating expenses of Zhejiang University under Grant No. 2019KZZX005-4-05 (to Y.L.), and Hepatobiliary and Pancreatic Cancer Research of Hubei Chen Xiaoguang and Science and Technology Development Foundation under Grant No. CJKJHL1900001-2019308 (to J.X.), CJKJHL1900001-2019209 (to X.C.) and CJKHNL1900009-03 (to X.L.).

AUTHOR CONTRIBUTIONS

J.X., L.J. and Y.L. conceived the project and performed most of the experiments. J.X. wrote the manuscript and collected the data. Z.W., H.L., X.Z., J.C., R.J. collected and analyzed the data. X.C., X.L., W.Z., X.S., K.G., L.J. and Q.S. contributed to the interpretation of the data and the critical review of the manuscript. X.C. and X.L. directed the project. X.C., J.X., Y.L. and X.L. provided the fundings for this study.

ADDITIONAL INFORMATION

The online version of this article (https://doi.org/10.1038/s41392-020-00375-5) contains supplementary material, which is available to authorized users.

Competing interests: The authors declare no competing interests.

REFERENCES

1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca: Cancer J. Clin. 68, 394–424 (2018).
2. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).
3. Villanueva, A. & Llovet, J. M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 140, 1410–1426 (2011).

Fig. 6 Silencing circRNA-SORE substantially improves sorafenib efficacy in vivo. a BALB/c nude mice (4- to 6-week-old males) were orthotopically implanted with SKHeP1-SR-luc-NC or SKHeP1-SR-luc-shcircRNA-SORE cells. On week 4, the mice were treated with sorafenib (30 mg/kg/day) for 4 weeks. In vivo luminescence was performed weekly starting on week 4. Animals were sacrificed on week 8. Luminescence intensity ranges from low (blue) to high (red). b BALB/c nude mice (4- to 6-week-old males) were subcutaneously injected with LM3-SR cells. On week 4, the mice were treated with sorafenib (30 mg/kg/day) for 4 weeks and then injected at the implantation site with in vivo-grade si-circRNA-SORE or si-NC twice a week for 2 weeks. Animals were sacrificed and the second-generation PDX was isolated on week 8. c NOD/SCID mice (4- to 6-week-old males) were subcutaneously implanted with HCC patient-derived xenograft (PDX) and treated with sorafenib (30 mg/kg/day) by oral gavage starting on week 4. Eight weeks later, the sorafenib-resistant xenograft was removed for a second round of orthotopic implantation. On week 4, the second PDX generation mice were treated with sorafenib (30 mg/kg/day) for 4 weeks and were injected at the implantation site with in vivo-grade si-circRNA-SORE or si-NC twice a week for 2 weeks. Animals were sacrificed and the second-generation PDX was isolated on week 8. d Immunohistochemistry for YBX1 in si-circRNA-SORE and si-NC LM3-SR xenografts. Scale bar, 50 μm. e Immunohistochemistry for YBX1 in si-circRNA-SORE and control PDX. Scale bar, 50 μm. f Model for circRNA-SORE-mediated sorafenib resistance in HCC. CircRNA-SORE is necessary for the development and maintenance of sorafenib resistance in HCC, and silencing circRNA-SORE substantially increases sorafenib-induced apoptosis. CircRNA-SORE specifically binds to the master oncogenic protein YBX1 and thus sequesters YBX1 in the cytoplasm, which prevents YBX1 ubiquitination and degradation by PRP19 in the nucleus. CircRNA-SORE is transmitted by exosomes, allowing for the spread of sorafenib resistance among HCC cells. Data are expressed as mean ± SEM (error bars). Statistical analyses used Student’s t test. ***p < 0.001
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by...
Xu et al.

4. Chen, J. et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 367, 1–11 (2015).

5. Memczak, S. et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333–338 (2013).

6. Hansen, T. B. et al. Natural RNA circles function as efficient microRNA sponges. Nature 495, 384–388 (2013).

7. Hansen, T. B., Kjems, J. & Damgaard, C. K. Circular RNA and miR-7 in cancer. Cancer Res. 73, 5609–5612 (2013).

8. Du, W. W. et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 44, 2846–2858 (2016).

9. Rak, J. & Guha, A. Extracellular vesicles–vehicles that spread cancer genes. Bioessays 34, 489–497 (2012).

10. Thery, C., Ostrowski, M. & Segura, E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9, 581–593 (2009).

11. El Andaloussi, S., Mäger, I., Breakefield, X. O. & Wood, M. J. A. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12, 347 (2013).

12. Qu, L. et al. Exosome-transmitted IncARS RM promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell 29, 653–668 (2016).

13. Qu, Z. et al. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. J. Exp. Clin. Cancer Res. 35, 159 (2016).

14. Li, Y. et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 25, 981–984 (2015).

15. Ashwal-Fluss, R. et al. circRNA biogenesis competes with pre-mRNA splicing. Mol. Cell 56, 55–66 (2014).

16. Hentze, M. W. & Preiss, T. Circular RNAs: splicing’s enigma variations. EMBO J. 32, 923–925 (2013).

17. Li, Z. et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat. Struct. Mol. Biol. 22, 256–264 (2015).

18. Zheng, Q. et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat. Commun. 7, 11215 (2016).

19. Dolfiini, D. & Mantovani, R. Targeting the V/CCAAT box in cancer: YB-1 (YBX1) or NF-Y? Cell Death Differ. 20, 676–685 (2013).

20. Lamash, A. et al. YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem. J. 449, 11–23 (2013).

21. Tang, Z. et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98–W102 (2017).

22. Chanarat, S. & Strasser, K. Splicing and beyond: the many faces of the Prp19 complex. Biochim. Biophys. Acta 1833, 2126–2134 (2013).

23. Marechal, A. et al. Prp19 transforms into a sensor of RPA-ssDNA after DNA damage and drives ATR activation via a ubiquitin-mediated circuitry. Mol. Cell 53, 235–246 (2014).

24. Moore, C., Kogsdudge, U., Lange, S. & Inal, J. M. The emerging role of exosome and microvesicles (EMVs) based cancer therapeutics and immunotherapy. Int. J. Cancer 141, 428–436 (2017).

25. Lu, Z. et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J. Hepatol. 67, 739–748 (2017).

26. Wang, F. et al. Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology 67, 940–954 (2018).

27. Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2016).

28. Llovet, J. M., Montal, R., Sia, D. & Finn, R. S. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 15, 599–616 (2018).

29. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

30. Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54–63 (2018).

31. Zhu, A. X. et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH Trial results by Child-Pugh score. JAMA Oncol. 3, 235–243 (2017).

32. Xu, J. et al. The miR-367-3p increases sorafenib chemotherapy efficiency to suppress hepatocellular carcinoma metastasis through altering the androgen receptor signals. Elife 12, 55–67 (2016).

33. Abou-Alfa, G. K. et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304, 2154–2160 (2010).

34. Xu, J. et al. Sorafenib with ASC-J9(R) synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/IKB2 signals. Int. J. Cancer 140, 705–717 (2017).

35. Zhang, Y. et al. Circular intronic long noncoding RNAs. Mol. Cell 51, 792–806 (2013).

36. Stein, C. A. & Castanotto, D. FDA-approved oligonucleotide therapies in 2017. Mol. Ther. 25, 1069–1075 (2017).

37. Lyu, D. & Huang, S. The emerging role and clinical implication of human exonic circular RNA. RNA Biol. 14, 1000–1006 (2017).

38. Loscher, M. et al. Interaction of U-box E3 ligase SNEV with PSMB4, the beta7 subunit of the 20 S proteasome. Biochem. J. 388, 593–603 (2005).

39. Sihn, C. R. et al. Mouse homologue of yeast Prp19 interacts with mouse SUG1, the regulatory subunit of 265 proteasome. Biochem. Biophys. Res. Commun. 356, 175–180 (2007).

40. Zhang, H. et al. Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7. Oncogene 38, 2844–2859 (2019).

41. Bureau of Medical Administration, National Health and Family Planning Commission of the People’s Republic of China. Standardization of diagnosis and treatment for hepatocellular carcinoma (2017 edition). Chin. J. Digest. Surg. 16, 635–647 (2017).

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.